Aculys Pharma Receives Marketing Approval for Spydia® Nasal Spray in Japan, an Immediate-Use Medication for Epileptic Seizures

Tokyo, Japan, June 24, 2025 ­– Aculys Pharma, Inc. (“Aculys”), a clinical stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions, announced that it has received marketing approval from the Ministry of Health, Labour and Welfare (MHLW) of Japan for “Spydia® Nasal Spray 5 mg, 7.5 mg, and 10 mg” (generic name: diazepam) […]